Clinical Trial Results: A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial results for CLE-100 (oral esketamine) as an adjunct to standard antidepressants in major depressive disorder have been completed with posted resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• CLE-100 (esketamine)

Snippet

Sponsor: Clexio Biosciences Ltd. | Conditions: Adjunctive Treatment of Major Depressive Disorder (MDD) | Phase 2 | Status: COMPLETED | Results posted: 2026-06-23